PRODUCT INFORMATION GSK2126458



ltem	No.	17	37	7
------	-----	----	----	---

CAS Registry No.:	1086062-66-9	F \sim F
Formal Name:	2,4-difluoro-N-[2-methoxy-5-	
	[4-(4-pyridazinyl)-6-quinolinyl]-3-	0
	pyridinyl]-benzenesulfonamide	
Synonyms:	GSK458, Omipalisib	
MF:	C ₂₅ H ₁₇ F ₂ N ₅ O ₃ S	
FW:	505.5	$H \qquad \qquad \downarrow \qquad \checkmark \qquad \checkmark \qquad \downarrow \qquad \qquad \downarrow$
Purity:	≥98%	
UV/Vis.:	λ _{max} : 225, 300 nm	0 N
Supplied as:	A crystalline solid	
Storage:	-20°C	
Stability:	≥4 years	IN IN

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

GSK2126458 is supplied as a crystalline solid. A stock solution may be made by dissolving the GSK2126458 in the solvent of choice, which should be purged with an inert gas. GSK2126458 is soluble in organic solvents such as DMSO and dimethyl formamide. The solubility of GSK2126458 in these solvents is approximately 5 and 1 mg/ml, respectively.

GSK2126458 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, GSK2126458 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. GSK2126458 has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

GSK2126458 is a potent inhibitor of phosphoinositide 3-kinase isoforms (K,s = 19, 130, 24, and 60 pM for p110 α , β , δ , and γ , respectively).¹ It also inhibits mTOR in both mTORC1 and mTORC2 (K,s = 180 and 300 nM, respectively), as well as several common mutant forms of p110 α .¹ GSK2126458 is orally bioavailable, displays favorable pharmacokinetics, and shows efficacy in tumor growth models.¹ GSK2126458 positively combines with inhibitors of discoidin domain receptor 1 (DDR1) inhibitor DDR1-IN-1 (Item No. 18092) to suppress the growth of SNU-1040 colorectal cancer cells.²

References

- 1. Knight, S.D., Adams, N.D., Burgess, J.L., et al. Discovery of GSK2126458, a highly potent inhibitor of P13K and the mammalian target of rapamycin. ACS Med. Chem. Lett. 1, 39-43 (2010).
- 2. Kim, H.G., Tan, L., Weisberg, E.L., et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol. 8(10), 2145-2150 (2013).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFFTY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/09/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM